Replies to post #439798 on NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Well Doc, since the Proneural group's survival is not promoted by the utilization of DCVax-L, I am not mourning the removal of this group from the trial because those patients would have diluted the survival advantage of the Treatment group vis a vis the Controls. However, I am guessing that many patients with the Proneural GBM demonstrated early pseudo-progression and had already been removed from the trial before randomization. So now we are rid of the remaining members of this group.

However, I am confident that we can rely especially on mesenchymal antigenic pattern to give us a homerun.

I don't know of treatments that are more successful in treating the most aggressive form of a primary cancer while being a much less successful treatment for a relatively milder antigenic form of the disease. in this respect, DCVax-L seems to be an exception.

[meirluc]

Sorry Doc, I got confused. You were writing about the effectiveness of DCVax-L in methylated mesenchymal GBM which is a far less pernicious cancer than the unmethylated form and I was referring to generally to mesenchymal cancer.

DCVax-L seems to have some value for GBM patients with the unmethylated form of mesenchymal GBM as I believe the 2018 JTM stated that about 14% of the blended patients with the unmethylated GBM were destined to become post 36 months survivors. That is a promising result especially since it included Control patients with the unmethylated form.

However, I agree that the real homerun will emerge from the methylated mesenchymal Treatment group.